Indirubin Derivative E804 is primarily investigated for its potential therapeutic applications, particularly in the field of cancer research. It has shown promising activity in inhibiting the growth of various cancer cell lines by targeting specific signaling pathways, such as the Wnt/β-catenin pathway, which is often dysregulated in cancers. Additionally, it exhibits anti-inflammatory properties, making it a candidate for treating inflammatory diseases. Research is ongoing to explore its efficacy in combination therapies and its role in reducing drug resistance in cancer treatment. Its application in neurodegenerative diseases is also being studied due to its neuroprotective effects.